| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CST6 |
| Uniprot No | Q15828 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-149aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMRPQERMVGELRDLSPDDPQVQKAAQAAVA SYNMGSNSIYYFRDTHIIKAQSQLVAGIKYFLTMEMGSTDCRKTRVTGDH VDLTTCPLAAGAQQEKLRCDFEVLVVPWQNSSQLLKHNCVQM |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CST6重组蛋白的3篇代表性文献的虚构示例(仅供格式参考，实际文献需查询数据库)：
---
1. **文献名称**：*Recombinant Human Cystatin 6 Inhibits Tumor Cell Invasion in Breast Cancer Models*
**作者**：Zhang L, et al.
**摘要**：本研究通过大肠杆菌表达系统成功制备了重组人CST6蛋白，并验证其抑制半胱氨酸蛋白酶(如组织蛋白酶B)的活性。实验表明，重组CST6可显著抑制乳腺癌细胞侵袭，提示其在肿瘤治疗中的潜在应用。
2. **文献名称**：*Structural and Functional Characterization of Recombinant CST6 in Ovarian Cancer*
**作者**：Wang Y, et al.
**摘要**：文章解析了重组CST6蛋白的晶体结构，并通过体外实验证明其通过调控蛋白酶活性抑制卵巢癌细胞迁移。研究为靶向CST6的抗癌药物设计提供了结构基础。
3. **文献名称**：*Expression and Purification of CST6 in Pichia pastoris: Implications for Epigenetic Therapy*
**作者**：Kim S, et al.
**摘要**：利用毕赤酵母系统高效表达重组CST6蛋白，优化纯化工艺后验证其生物活性。研究发现，CST6可逆转肿瘤细胞的异常DNA甲基化，增强化疗敏感性。
---
**注**：以上文献为示例性质，实际研究需通过PubMed、Web of Science等数据库检索关键词(如"recombinant CST6"、"Cystatin 6 expression")。真实文献可能涉及CST6在癌症、免疫调控或蛋白酶抑制中的机制研究。
Cystatin E/M (CST6), a member of the type 2 cystatin family, is a secreted protein encoded by the *CST6* gene, located on human chromosome 11q13. It functions as a potent endogenous inhibitor of cysteine proteases, particularly cathepsins B, L, and S, which are implicated in extracellular matrix degradation, tumor invasion, and metastasis. CST6 plays a critical role in maintaining protease-antiprotease balance, regulating cellular processes such as apoptosis, inflammation, and tissue remodeling.
Originally identified as a tumor suppressor, CST6 is frequently epigenetically silenced in various cancers, including breast, lung, and head and neck carcinomas. Promoter hypermethylation and histone modification are primary mechanisms driving its downregulation, correlating with poor prognosis and aggressive tumor behavior. In breast cancer, for instance, loss of CST6 expression enhances cathepsin-mediated proteolysis, facilitating tumor cell migration, invasion, and metastasis. Conversely, restoring CST6 expression inhibits these processes, highlighting its therapeutic potential.
Recombinant CST6 protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells) to study its biochemical and functional properties. This engineered protein retains the ability to bind and inhibit target proteases, making it a valuable tool for investigating tumor biology, drug discovery, and protease-related pathologies. Studies also explore its role in non-cancer contexts, such as inflammatory diseases and neurodegenerative disorders linked to cysteine protease dysregulation.
Current research focuses on CST6's dual role in tumor suppression and immune modulation, as well as strategies to reactivate its expression using demethylating agents or gene therapy. Its potential as a biomarker for early cancer detection or therapeutic response is under active investigation.
×
